Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 5
2004 7
2005 13
2006 8
2007 11
2008 7
2009 7
2010 5
2011 7
2012 8
2013 20
2014 20
2015 16
2016 22
2017 16
2018 20
2019 17
2020 28
2021 32
2022 31
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Results by year

Filters applied: . Clear all
Page 1
A new era in the science and care of kidney diseases.
Zoccali C, Mallamaci F, Lightstone L, Jha V, Pollock C, Tuttle K, Kotanko P, Wiecek A, Anders HJ, Remuzzi G, Kalantar-Zadeh K, Levin A, Vanholder R. Zoccali C, et al. Among authors: pollock c. Nat Rev Nephrol. 2024 Apr 4. doi: 10.1038/s41581-024-00828-y. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 38575770 Review.
Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial.
Koshino A, Neuen BL, Oshima M, Toyama T, Hara A, Arnott C, Neal B, Jardine M, Badve SV, Mahaffey KW, Pollock C, Hansen MK, Wada T, Heerspink HJL. Koshino A, et al. Among authors: pollock c. Kidney Int Rep. 2023 Dec 1;9(2):347-355. doi: 10.1016/j.ekir.2023.11.024. eCollection 2024 Feb. Kidney Int Rep. 2023. PMID: 38344715 Free PMC article.
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL. Koshino A, et al. Among authors: pollock c. Cardiovasc Diabetol. 2023 Nov 28;22(1):330. doi: 10.1186/s12933-023-02027-8. Cardiovasc Diabetol. 2023. PMID: 38017482 Free PMC article. Clinical Trial.
300 results